Oak Associates’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-5,284
| Closed | -$1.15M | – | 136 |
|
|
2022
Q4 | $1.15M | Sell |
5,284
-1,000
| -16% | -$218K | 0.1% | 102 |
|
|
2022
Q3 | $1.24M | Hold |
6,284
| – | – | 0.11% | 91 |
|
|
2022
Q2 | $1.34M | Hold |
6,284
| – | – | 0.11% | 87 |
|
|
2022
Q1 | $1.78M | Sell |
6,284
-600
| -9% | -$185K | 0.11% | 88 |
|
|
2021
Q4 | $2.59M | Sell |
6,884
-3,874
| -36% | -$1.51M | 0.14% | 72 |
|
|
2021
Q3 | $4.44M | Sell |
10,758
-1,612
| -13% | -$669K | 0.25% | 57 |
|
|
2021
Q2 | $4.58M | Sell |
12,370
-150
| -1% | -$50.1K | 0.26% | 54 |
|
|
2021
Q1 | $3.63M | Sell |
12,520
-1,445
| -10% | -$402K | 0.21% | 56 |
|
|
2020
Q4 | $3.49M | Hold |
13,965
| – | – | 0.21% | 57 |
|
|
2020
Q3 | $3.16M | Sell |
13,965
-3,150
| -18% | -$654K | 0.21% | 60 |
|
|
2020
Q2 | $2.98M | Sell |
17,115
-880
| -5% | -$140K | 0.2% | 62 |
|
|
2020
Q1 | $2.27M | Hold |
17,995
| – | – | 0.19% | 65 |
|
|
2019
Q4 | $2.75M | Hold |
17,995
| – | – | 0.16% | 73 |
|
|
2019
Q3 | $2.38M | Hold |
17,995
| – | – | 0.15% | 78 |
|
|
2019
Q2 | $2.55M | Hold |
17,995
| – | – | 0.16% | 78 |
|
|
2019
Q1 | $2.61M | Sell |
17,995
-4,435
| -20% | -$583K | 0.16% | 73 |
|
|
2018
Q4 | $2.54M | Hold |
22,430
| – | – | 0.18% | 77 |
|
|
2018
Q3 | $3.02M | Sell |
22,430
-700
| -3% | -$86.4K | 0.18% | 79 |
|
|
2018
Q2 | $2.6M | Hold |
23,130
| – | – | 0.17% | 82 |
|
|
2018
Q1 | $2.47M | Hold |
23,130
| – | – | 0.17% | 82 |
|
|
2017
Q4 | $2.53M | Sell |
23,130
-5,320
| -19% | -$579K | 0.18% | 80 |
|
|
2017
Q3 | $3.07M | Hold |
28,450
| – | – | 0.23% | 83 |
|
|
2017
Q2 | $2.88M | Sell |
28,450
-300
| -1% | -$27.6K | 0.22% | 86 |
|
|
2017
Q1 | $2.59M | Sell |
28,750
-1,650
| -5% | -$140K | 0.21% | 91 |
|
|
2016
Q4 | $2.32M | Sell |
30,400
-1,200
| -4% | -$91.1K | 0.23% | 93 |
|
|
2016
Q3 | $2.4M | Sell |
31,600
-1,300
| -4% | -$109K | 0.25% | 89 |
|
|
2016
Q2 | $2.71M | Buy |
32,900
+600
| +2% | +$49.4K | 0.33% | 75 |
|
|
2016
Q1 | $2.45M | Hold |
32,300
| – | – | 0.3% | 77 |
|
|
2015
Q4 | $2.6M | Hold |
32,300
| – | – | 0.31% | 76 |
|
|
2015
Q3 | $2.05M | Buy |
32,300
+4,400
| +16% | +$316K | 0.27% | 80 |
|
|
2015
Q2 | $1.96M | Hold |
27,900
| – | – | 0.24% | 90 |
|
|
2015
Q1 | $2.21M | Hold |
27,900
| – | – | 0.27% | 83 |
|
|
2014
Q4 | $1.78M | Buy |
27,900
+1,600
| +6% | +$100K | 0.21% | 93 |
|
|
2014
Q3 | $1.57M | Buy |
26,300
+2,800
| +12% | +$160K | 0.19% | 98 |
|
|
2014
Q2 | $1.26M | Buy |
+23,500
| New | +$1.29M | 0.15% | 107 |
|
Other funds holding CRL
JSP
Oak Associates's CRL Position: Q1 2023 in Review
Oak Associates sold out of Charles River Laboratories (CRL) in Q1 2023, closing a stake of 5,284 shares — an estimated $1.15M sold.
Oak Associates first reported a position in CRL in Q2 2014 and held it in 35 quarters. The position peaked at $4.58M in Q2 2021. 620 funds tracked by Wall St. Rank hold CRL as of Q1 2023.
- Oak Associates reported no remaining Charles River Laboratories position as of Q1 2023 after selling out during the quarter.
- Oak Associates sold 5,284 Charles River Laboratories shares in Q1 2023, an estimated $1.15M.
- Oak Associates first reported a position in Charles River Laboratories in Q2 2014 and held it in 35 quarters.
- Oak Associates's Charles River Laboratories position peaked at $4.58M in Q2 2021.
- 620 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2023.
Based on Oak Associates's 13F filing for Q1 2023, filed 11 May 2023.